The laboratories of K Fuse (Sweden), L Agnate (Italy), R Franco (Spain), M Bader (Germany), J Schell-Kruger (Neurosearch, Denmark), A Rankin (Estonia) and S.Schiffmann (Belgium) regroup for the project. This consortium has recently demonstrated that adenosine (Ado) /dopamine (DA) receptor (R) heteromerization playa important role in striate neuronal functions. These results open new perspectives for the knowledge and therapy of neurological diseases. The project aims towards
1) Understanding the structural and molecular basis of Ado/DA R heteromerization;
2) Understanding the role of Ado/DA heteromers in cell function and strictly regulated functions, also involving the study of knock-in mice with mutated A2A and D2 R lacking the ability to heteromerize;
3) Preclinical development of novel A2A and A1 compounds target in the A2A/D2 and A1 /D1 heteromers, respectively, for treatment of Parkinson's disease (PD).
Funding SchemeCSC - Cost-sharing contracts